(Q30151392)

7 June 2017

Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C. (English)

1 reference

7 June 2017

1 reference

1 reference

9

Brian J McMahon

1 reference

7 June 2017

Stephen E Livingston

1

1 reference

7 June 2017

Lisa J Townshend-Bulson

2

1 reference

7 June 2017

Dana J T Bruden

3

1 reference

7 June 2017

Chriss E Homan

4

1 reference

7 June 2017

James E Gove

5

1 reference

7 June 2017

Julia N Plotnik

6

1 reference

7 June 2017

Brenna C Simons

7

1 reference

7 June 2017

Philip R Spradling

8

1 reference

7 June 2017

1 January 2016

1 reference

International Journal of Circumpolar Health

7 June 2017

1 reference

7 June 2017

75

1 reference

7 June 2017

30696

1 reference

7 June 2017

1

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

7 June 2017

1 reference

https://api.crossref.org/works/10.3402%2FIJCH.V75.30696

Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FIJCH.V75.30696

Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FIJCH.V75.30696

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FIJCH.V75.30696

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.3402%2FIJCH.V75.30696

Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Outcomes for Indigenous and non-Indigenous patients who access treatment for hepatitis C in the Top End of the Northern Territory.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Hepatitis C treatment among racial and ethnic groups in the IDEAL trial

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Gender influence on treatment of chronic hepatitis C genotype 1.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Hepatitis C treatment completion rates in routine clinical care

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Diagnosis, management, and treatment of hepatitis C: an update

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Hepatitis C virus infection in African Americans

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Estimating the date of hepatitis C virus infection from patient interviews and antibody tests on stored sera

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Epidemiology and risk factors for hepatitis C in Alaska Natives

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4814572

26 November 2018

Identifiers

DOI

10.3402/IJCH.V75.30696

1 reference

7 June 2017

0 references

1 reference